Pentixapharm AG

Pentixapharm is a radiopharmaceutical development company founded in 2019, with its headquarters in Würzburg, Germany. Its clinical pipeline encompasses PentixaTher, an Yttrium-90 based therapeutic against CNS lymphoma, and PentixaFor, a Gallium-68 based companion diagnostic. Clinical studies for both compounds have already commenced in Europe, with a dose-finding study for PentixaTher and a Phase III registration study for PentixaFor. Additionally, PentixaFor is being developed as a diagnostic tool for primary aldosteronism (PA), a significant cause of hypertension.